多巴胺受体激动剂联合左旋多巴治疗帕金森病的临床效果

Clinical efficacy of dopamine receptor agonists combined with levodopa in the treatment of Parkinson's disease

目的探讨多巴胺受体激动剂联合左旋多巴治疗帕金森病的临床效果。方法选取2014年1月至2016年12月收治的90例帕金森病患者作为研究对象,按数字表法分为两组,每组45例。对照组单用左旋多巴进行治疗,试验组联合应用多巴胺受体激动剂与左旋多巴治疗,比较两组的临床疗效,治疗前、后帕金森病评分量表(UPDRS)评分以及不良反应发生情况。结果治疗后,两组患者的UPDRS评分均显著降低,且试验组低于对照组(P<0.05)。试验组的临床疗效显著优于对照组(P<0.05)。试验组不良反应总发生率略高于对照组,差异不具有统计学意义(P>0.05)。结论联合应用多巴胺受体激动剂和左旋多巴可改善帕金森病患者UPDRS评分,疗效显著且安全性高,值得临床应用推广。

Objective To investigate the clinical efficacy of dopamine receptor agonists combined with levodopa in the treatment of Parkinson’s disease. Methods Ninety patients with Parkinson’s disease were collected as the study objects from January 2014 to December 2016,and divided into two groups according to the number table method,with 45 cases in each group. The control group was treated with levodopa alone. The experimental group was treated with a combination of dopamine receptor agonists and levodopa. The clinical efficacy, uniform parkinson’s disease rating scale（UPDRS） scores before and after treatment and occurrence of adverse reactions between the two groups were compared. Results After treatment, the UPDRS scores of both groups significantly decreased, and that in the experimental group was lower than the control group（P〈0.05）. The clinical efficacy of the experimental group was significantly better than that of the control group（P〈0.05）. The total incidence of adverse reactions in the experimental group was slightly higher than that in the control group,the difference was not statistically significant（P〉0.05）. Conclusion Dopamine receptor agonists combined with levodopa can improve the UPDRS score of patients with Parkinson’s disease, the efficacy is significant and the safety is high, which is worthy of clinical application.